ASH 2022: Safety and Efficacy of Ruxolitinib in CMML
Posted: 01/18/2023 | By: Kayci Reyer

A phase II clinical trial presened by Padron et al in 2022 American Society of Hematology (ASH) Annual Meeting and Exposition investigated the efficacy of ruxolitinib for the treatment of chronic myelomonocytic leukemia (CMML) by objectively measuring responses and symptom improvement (Abstract 457).

Question 1 of 5

This phase II clinical trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML) objectively measured responses of which organ?

Choose 1